SCOTUSBlog

MARCH 23, 2023

Sanofi , the justices will consider whether Amgen’s patent is too broad to be valid under federal patent rules. Amgen and other companies already have patents covering particular antibodies defined by their amino acid sequences. Sanofi claims that what Amgen did in this case was “claim a lot and disclose a little.”

Court 103

Court Statute Government Laws 103

Law 360

MAY 20, 2024

shareholders Monday that it is ending its fight to remove certain members of the biotech company's board, citing its favorable view of Novavax's licensing deal with Sanofi earlier this month. Hedge fund Shah Capital Management Inc. told fellow Novavax Inc.

52

52

Law 360

JULY 21, 2022

Denner decision, that Bioverativ directors may have breached their fiduciary duties when Sanofi purchased the company, expands the court's approach on director independence, severance-related conflicts and gaps in board minutes, say attorneys at Fried Frank. The Delaware Chancery's recent Goldstein v.

Attorney 52

Attorney Court 52

Law 360

MAY 6, 2024

Supreme Court rejected Vanda Pharmaceuticals' request to review of the Federal Circuit’s reasonable expectation of success standard for determining obviousness, including that the court was unpersuaded by the company's argument that Amgen v. Sanofi places a bind on drug developers.

Court 52

Court Attorney 52

Mondaq

DECEMBER 5, 2021

Well known life sciences company, Sanofi and it's Chinese brand name ‘赛诺菲' are highly regarded in the Chinese market.

40

40

Patently O

APRIL 21, 2022

Sanofi, et al., Becton, Dickinson and Company , No. Scope and Procedure for the Enablement Requirement: Amgen Inc., 21-757 (CVSG requested April 18, 2022); Infringement and Damages: Do Enhanced Damages Require “Egregious Behavior” : Cisco Systems, Inc. SRI International, Inc. ,

Laws 83

Laws Court Construction Manufacturing 83

Law 360

APRIL 17, 2023

will seek an up to $21 million award for their work brokering an $84 million deal to partially settle a class challenge in Delaware Chancery Court to the company's sale to Sanofi in 2018. Attorneys representing stockholders of Bioverativ Inc.

Attorney 40

Attorney Court 40

Law 360

JUNE 2, 2022

Denner and the activist hedge fund he controlled must face insider trading claims in a Delaware Chancery Court lawsuit alleging an unfair deal process behind the company's $11.6 billion sale to Sanofi in 2018.

Court 40

Court 40

Law 360

FEBRUARY 13, 2023

The federal government, various drug companies and a molecular biologist who won the Nobel Prize for his work with monoclonal antibodies urged the U.S. Supreme Court to keep the standard of patent enablement as is, backing Sanofi and Regeneron in their fight against Amgen.

Court 40

Court Government 40

Law 360

DECEMBER 15, 2022

a hemophilia-focused biopharm that Sanofi SA bought in 2018, has sued both companies in Delaware Chancery Court, alleging they have refused to pay his legal fees in an ongoing shareholder suit accusing him of insider trading ahead of the $11.6 A former board member of Bioverativ Inc., billion merger.

Legal 40

Legal Legal Court 40

Patently O

MAY 1, 2023

A skinny-label occurs when a generic drug company seeks approval for a drug with a label that omits the patented indications of the brand-name drug. Sanofi case, argued in March 2023. GlaxoSmithKline LLC , No. Polar Electro Oy , No. In addition, the Supreme Court has yet to rule on the Amgen v.

Court 81

Court Technology 81

Patently O

APRIL 15, 2021

In this case, the employee started his own competing company and was sued for patent infringement. Kingston Technology Company, Inc., Furniture Company, Inc. Sanofi-Aventis U.S. The lower court barred an invalidity defense. 19-1459; Comcast Cable Communications, LLC v. Promptu Systems Corporation, et al. , Iancu , No.

Laws 83

Laws Court Technology Construction 83

FDA Law Blog

FEBRUARY 5, 2023

By Faraz Siddiqui — In the Spring of 2021, the Health Resources and Services Administration (HRSA) threatened six drug companies with billions of dollars in penalties for not providing 340B discounts to covered entities that sell drugs through vast networks of contract pharmacies (more background on earlier posts ).

Contract 52

Contract Statute Manufacturing Court 52

FDA Law Blog

OCTOBER 6, 2021

are diverting drugs purchased at low 340B prices to non-340B patients, the companies are declining to sell drugs to 340B covered entities that use multiple contract pharmacies. 12, 2021); Sanofi-Aventis U.S., Because of concerns that these contract pharmacies, which include some of the largest chains in the U.S., Becerra , No.

Manufacturing 52

Manufacturing Contract Statute Court 52

Patently O

FEBRUARY 24, 2022

Sanofi has the potential of being a huge case in terms of how it impacts the future of biotech innovation. .” And, rather than basing its argument on the 7th Amendment, Daikin’s petition is grounded in the Administrative Procedure Act and “the principles of separation of powers embedded within that Act.”

Laws 95

Laws Court Litigating Litigation 95

LegalReader

MARCH 5, 2021

Appeals court decision has far-reaching implications for drug patents.

Court Decisions 76

Court Decisions Court 76

Patently O

NOVEMBER 29, 2023

23-491 This case arises from multiple patent infringement lawsuits filed by Realtime Data LLC (d/b/a IXO) against various technology companies, including Fortinet, Inc., Sanofi, 142 S. Fortinet, No. Reduxio Systems, Inc., and others in the District of Delaware. 101 as claiming only abstract ideas and no inventive concept. 1713 (2022).

Prima Facie Case 75

Prima Facie Case Court Laws Technology 75

SCOTUSBlog

NOVEMBER 2, 2022

approximately $90 million in damages for Lanham Act violations by Abitron Austria GmbH and affiliated German and Austrian corporation defendants — including a sibling company named “Hetronic Germany GmBH,” which may give you some idea of the basis for the suit. Sanofi , 21-757. Before the U.S. Then comes Amgen v. Navajo Nation.

Government 106

Government Construction Court Statute 106

SCOTUSBlog

MAY 19, 2023

The justices ruled in favor of social media companies in Twitter, Inc. The chief finishes reading the letters and it is on to a (very) busy day of opinions. Justice Neil Gorsuch has the first opinion for a unanimous court in the patent case Amgen v. It is the first opinion from the March sitting. Federal Labor Relations Authority.

Law School 85

Law School Lawyer Lawyers Administrative Law 85

FDA Law Blog

FEBRUARY 4, 2025

vivax malaria relapse Feb 2019 Egaten (Novartis) Fascioliasis (used) May 2019 Dengvaxia (Sanofi) Dengue disease vaccine Aug 2019 Pretomanid (TB Alliance) MDR pulmonary TB Dec 2019 Ervebo (Merck) Ebolavirus vaccine $ 100 (UNK) Aug 2020 Lampit (Bayer) Chagas disease caused by T.

Drafting 52

Drafting Manufacturing Laws 52